• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Conferences

Conferences
Conferences RSS Feed RSS

Cancer

HSK-46256, a brain-penetrant PARP-1 inhibitor for the treatment of HRD-associated tumors

May 6, 2025
No Comments
PARP inhibitors have been approved for the treatment of several cancers, including ovarian, breast, pancreatic and prostate cancers with BRCA mutations or other homologous recombination repair deficiencies (HRD). However, their therapeutic potential is limited by challenges such as hematologic toxicity and lack of target selectivity.
Read More
Concept art for targeting cancer
Cancer

Dual-blocking anti-PD-1/VEGF bispecific conjugate demonstrates robust antitumor efficacy

May 5, 2025
No Comments
Programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) are often co-expressed in the tumor microenvironment. The combination of anti-PD-1 and anti-VEGF agents has been evaluated in patients with advanced non-small-cell lung cancer, with promising results from agents like ivonescimab, a PD-1/VEGF bispecific antibody.
Read More
Immuno-oncology

KGX-105 shows promising preclinical profile as cancer immunotherapeutic

May 5, 2025
No Comments
Kangabio Co. Ltd. has developed and presented data for their EGFRxCD3 TCE prodrug KGX-105 for the treatment of EGFR-expressing solid tumors.
Read More
Immuno-oncology

Tyligand develops new dual-action tumor immune agonists for cancer treatment

May 5, 2025
No Comments
Tyligand Bioscience Ltd. has reported data on TSN-222, their new cyclic dinucleotide designed as a dual-action tumor immune agonist (DATIA) compound.
Read More
Cancer

Astrazeneca’s AZD-0022 solid preclinical results support further development

May 5, 2025
No Comments
Astrazeneca plc recently reported new preclinical data regarding their KRAS G12D inhibitor AZD-0022, currently in phase I/II clinical studies. The company presented the pharmacokinetic and pharmacodynamic profiling of the compound with the aim to push forward with its clinical development.
Read More
3D illustration of tumor
Immuno-oncology

SOT-106: a next-gen LRRC15-directed ADC for sarcoma and aggressive solid tumors

May 2, 2025
No Comments
The leucine-rich repeat-containing protein 15 (LRRC15) is a cell surface protein involved in cell-cell and cell-matrix interactions, with limited expression in normal tissues.
Read More
Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow
Immuno-oncology

Bispecific antibody GEN-1057 induces apoptosis through DR4 and FAPα dual engagement

May 2, 2025
No Comments
The use of mimicking antibodies that activate death receptors (DRs) to selectively induce cell death in cancer cells has shown limited clinical success so far, primarily due to suboptimal efficacy and safety concerns, particularly hepatotoxicity. Emerging strategies to enhance efficacy include the development of bispecific antibodies that simultaneously target DRs and tumor-specific antigens.
Read More
Cancer

Selective BCL6 degrader for B-cell malignancies exhibits robust preclinical activity

May 2, 2025
No Comments
The transcriptional repressor B-cell lymphoma 6 (BCL6) plays a central role in the development and progression of various B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), where it is associated with poor prognosis and resistance to standard immunochemotherapy.
Read More
AI generated, 3D rendering of protein degradation
Cancer

AACR 2025: Induced proximity strategy, beyond degraders

May 2, 2025
By Anette Breindl
No Comments
Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical validation appears to be a matter of time.
Read More
Bladder

AUA hoorays in bladder cancer for J&J, Urogen, more

May 1, 2025
By Randy Osborne
Clinical results offered at the recent meeting of the American Urological Association in Las Vegas signal that better treatments may lie ahead for non-muscle invasive bladder cancer.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 3137 3138 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 15, 2025.
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • Freestyle Libre 3 sensor with smartphone app

    Abbott studies show CGM users have fewer hospitalizations

    BioWorld MedTech
    A pair of studies published in Diabetologia demonstrate that use of continuous glucose monitors (CGMs) reduces hospitalizations in people with type 1 diabetes and...
  • Hand cupping ear to illustration hearing loss

    Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug

    BioWorld
    Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe